Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter acquired 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The stock was acquired at an average cost of $3.53 per share, with a total value of $176,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Vital Therapies, Inc. (NASDAQ VTL) opened at 4.05 on Thursday. Vital Therapies, Inc. has a 1-year low of $2.25 and a 1-year high of $6.58. The firm has a 50-day moving average of $2.93 and a 200 day moving average of $3.35. The stock’s market capitalization is $170.94 million.

Vital Therapies (NASDAQ:VTL) last issued its earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.01. During the same quarter in the prior year, the business posted ($0.30) EPS. Analysts predict that Vital Therapies, Inc. will post ($1.31) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/14/muneer-a-satter-acquires-50000-shares-of-vital-therapies-inc-vtl-stock.html.

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in shares of Vital Therapies during the first quarter worth $167,000. Goldman Sachs Group Inc. boosted its position in shares of Vital Therapies by 1.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after acquiring an additional 1,157 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Vital Therapies by 11.5% during the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock worth $352,000 after acquiring an additional 9,120 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Vital Therapies during the second quarter worth $268,000. Finally, Blair William & Co. IL boosted its position in shares of Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after acquiring an additional 40,000 shares during the last quarter. Hedge funds and other institutional investors own 25.58% of the company’s stock.

VTL has been the subject of several analyst reports. Raymond James Financial, Inc. initiated coverage on shares of Vital Therapies in a report on Thursday, May 18th. They issued an “outperform” rating and a $6.00 price objective for the company. ValuEngine cut shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $8.00.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.